Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-02-2009 | Preclinical Study

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients

Authors: Nan-Yan Rao, Zhen Hu, Wen-Feng Li, Juan Huang, Zhong-Liang Ma, Bin Zhang, Feng-Xi Su, Jie Zhou, Gen-Hong Di, Kun-Wei Shen, Jiong Wu, Jin-Song Lu, Jian-Min Luo, Wen-Tao Yuan, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Purpose Our aim was to find an appropriate method to estimate the likelihood that a family history of cancer was a result of a mutation in the BRCA1 or BRCA2 genes. We also compared the performance of the established method with three different methods (Couch, Sh-E and BRCApro) to identify an alternative strategy for genetic council targeted to the specified population. Patients and methods The family history as well as individual information of two hundred unrelated probands who had completed BRCA1 and BRCA2 mutation screening was analyzed to assess the likelihood of a pathogenic mutation. A model was developed by empirical method. The performance of this model was validated in a separate patient cohort compared with BRCApro. Results Several factors were associated with mutations in univariate analysis and a logistic model was devised to estimate the probability for a proband of harboring a mutation in BRCA1 and/or BRCA2. Using a greater than 10% probability threshold, the highest accuracy was achieved by the established model when compared to other three models, presenting the highest sensitivity, PPV, NPV and area under ROC curve. The empirical model showed a better ROC curve compared to BRCApro in the verification cohort. Conclusion A probability model targeted to Han Chinese population should be a useful tool in the genetic counseling for the specified ethnic. Its ability to predict BRCA2 mutation carriers needs to be improved.
Literature
1.
go back to reference Hall JM et al (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689PubMedCrossRef Hall JM et al (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689PubMedCrossRef
2.
go back to reference Miki Y et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef Miki Y et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef
3.
go back to reference Wooster R et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265(5181):2088–2090PubMedCrossRef Wooster R et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265(5181):2088–2090PubMedCrossRef
4.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef
5.
go back to reference Hoskins KF et al (1995) Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 273(7):577–585PubMedCrossRef Hoskins KF et al (1995) Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 273(7):577–585PubMedCrossRef
6.
go back to reference Couch FJ et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415PubMedCrossRef Couch FJ et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415PubMedCrossRef
7.
go back to reference Shattuck-Eidens D et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250PubMedCrossRef Shattuck-Eidens D et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250PubMedCrossRef
8.
go back to reference Iversen ES, Parmigiani G, Berry DA et al (2000) Genetic susceptibility and survival: Application to breast cancer. J Am Stat Assoc 95:28–42 Iversen ES, Parmigiani G, Berry DA et al (2000) Genetic susceptibility and survival: Application to breast cancer. J Am Stat Assoc 95:28–42
9.
go back to reference Berry DA et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712PubMedCrossRef Berry DA et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712PubMedCrossRef
10.
go back to reference Li WF et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat, 13 September, Online Li WF et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat, 13 September, Online
11.
go back to reference Couch FJ et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415PubMedCrossRef Couch FJ et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415PubMedCrossRef
12.
go back to reference Hakansson S et al (1997) Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 60(5):1068–1078PubMed Hakansson S et al (1997) Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 60(5):1068–1078PubMed
13.
go back to reference Fearon ER (1997) Human cancer syndromes: clues to the origin and nature of cancer. Science 278(5340):1043–1050PubMedCrossRef Fearon ER (1997) Human cancer syndromes: clues to the origin and nature of cancer. Science 278(5340):1043–1050PubMedCrossRef
14.
go back to reference Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89(3):227–238PubMedCrossRef Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89(3):227–238PubMedCrossRef
15.
go back to reference Foulkes WD et al (1999) The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet 65(6):1776–1779PubMedCrossRef Foulkes WD et al (1999) The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet 65(6):1776–1779PubMedCrossRef
16.
go back to reference Hodgson SV et al (1999) Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet 36(5):369–373PubMed Hodgson SV et al (1999) Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet 36(5):369–373PubMed
17.
go back to reference Hopper JL, Jenkins MA (1999) Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet 65(6):1771–1776PubMedCrossRef Hopper JL, Jenkins MA (1999) Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet 65(6):1771–1776PubMedCrossRef
18.
go back to reference Chang-Claude J et al (1999) Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC demonstration project on familial breast cancer. Dis Markers 15(1–3):53–65PubMed Chang-Claude J et al (1999) Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC demonstration project on familial breast cancer. Dis Markers 15(1–3):53–65PubMed
19.
go back to reference Vahteristo P et al (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84(5):704–708PubMedCrossRef Vahteristo P et al (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84(5):704–708PubMedCrossRef
20.
go back to reference Kang HH et al (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914–920PubMedCrossRef Kang HH et al (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914–920PubMedCrossRef
21.
go back to reference James PA et al (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24(4):707–715PubMedCrossRef James PA et al (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24(4):707–715PubMedCrossRef
22.
go back to reference Gayther SA et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation. Nat Genet 11(4):428–433PubMedCrossRef Gayther SA et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation. Nat Genet 11(4):428–433PubMedCrossRef
23.
go back to reference Couch FJ et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123–125PubMedCrossRef Couch FJ et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123–125PubMedCrossRef
24.
go back to reference Gallardo M et al (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95(1):81–87PubMedCrossRef Gallardo M et al (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95(1):81–87PubMedCrossRef
25.
go back to reference McChesney PA et al (2006) Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res 66(3):1346–1353PubMedCrossRef McChesney PA et al (2006) Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res 66(3):1346–1353PubMedCrossRef
26.
go back to reference Smalley M, Ashworth A (2003) Stem cells and breast cancer: a field in transit. Nat Rev Cancer 3(11):832–844PubMedCrossRef Smalley M, Ashworth A (2003) Stem cells and breast cancer: a field in transit. Nat Rev Cancer 3(11):832–844PubMedCrossRef
27.
28.
go back to reference Levy-Lahad E et al (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98(6):3232–3236PubMedCrossRef Levy-Lahad E et al (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98(6):3232–3236PubMedCrossRef
29.
go back to reference Kadouri L et al (2004) A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90(10):2002–2005PubMedCrossRef Kadouri L et al (2004) A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90(10):2002–2005PubMedCrossRef
30.
go back to reference Vaziri SA et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7(7):1937–1945PubMed Vaziri SA et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7(7):1937–1945PubMed
31.
go back to reference Foulkes WD et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10(6):2029–2034PubMedCrossRef Foulkes WD et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10(6):2029–2034PubMedCrossRef
32.
go back to reference Eerola H et al (2005) Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7(4):R465–R469PubMedCrossRef Eerola H et al (2005) Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7(4):R465–R469PubMedCrossRef
Metadata
Title
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients
Authors
Nan-Yan Rao
Zhen Hu
Wen-Feng Li
Juan Huang
Zhong-Liang Ma
Bin Zhang
Feng-Xi Su
Jie Zhou
Gen-Hong Di
Kun-Wei Shen
Jiong Wu
Jin-Song Lu
Jian-Min Luo
Wen-Tao Yuan
Zhen-Zhou Shen
Wei Huang
Zhi-Ming Shao
Publication date
01-02-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9965-9

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine